Department of Rheumatology, First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.
Menzies Institute for Medical Research, University of Tasmania, Hobart, Tasmania, Australia.
J Cachexia Sarcopenia Muscle. 2023 Jun;14(3):1146-1149. doi: 10.1002/jcsm.13200. Epub 2023 Apr 18.
Vitamin D deficiency is a globally common situation and closely related with many chronic diseases. It is a hot topic to examine if vitamin D supplementation is effective for the treatment of diseases, and there have been dozens of clinical trials published in recent years. However, most studies have not proved the extra-skeletal benefits of vitamin D supplementation on these diseases. Some inherent shortcomings of these trials, such as inclusion with vitamin D-sufficient and obese participants, low response rate from participants and the insensitive changes in chosen outcomes over a shorter period, may be main reasons why most studies have yet to demonstrate effects of vitamin D supplementation. In this editorial, we aim to discuss the perspectives on how can we design a proper trial for vitamin D treatment of diseases based on the evidence-based practice framework PICOS (participants, intervention, control, outcomes and study design) in the future. First, right participants should be chosen, which is crucial for the success of vitamin D clinical trials. Participants with vitamin D sufficiency (e.g., baseline 25(OH)D of >50 nmol/L), obesity (e.g., body mass index > 30 kg/m ) and/or high vitamin D response index could be excluded from the trials. Second, intervention with vitamin D in right forms or dosages should be used. Vitamin D supplementation with appropriate dosages that keep 25(OH)D levels between 75 and 100 nmol/L is recommended. Third, 'contamination' in the control groups needs to pay attention. To diminish this, it is ideal to include participants less interfered by sun exposure (such as living in places at a high latitude) or with greater compliance (less interference by supplemental vitamin D-containing nutrients). Fourth, the outcome measures should be sensitive to change to avoid type II error. For outcomes such as bone density, radiographic osteoarthritis and cardiovascular diseases, follow-up period of 3-5 years may be required to observe the changes. Last, precision clinical trials may be the only way to prove the benefits of vitamin D supplementation.
维生素 D 缺乏是一种全球普遍存在的情况,与许多慢性疾病密切相关。评估维生素 D 补充是否对疾病治疗有效是一个热门话题,近年来已发表了数十项临床试验。然而,大多数研究并未证明维生素 D 补充对这些疾病的骨骼外益处。这些试验存在一些固有缺陷,例如纳入维生素 D 充足和肥胖的参与者、参与者的低反应率以及在较短时间内选择的结局变化不敏感,这可能是大多数研究尚未证明维生素 D 补充效果的主要原因。在这篇社论中,我们旨在根据基于循证实践框架 PICOS(参与者、干预、对照、结局和研究设计)的未来,讨论如何设计适当的维生素 D 治疗疾病的试验。首先,应该选择合适的参与者,这对维生素 D 临床试验的成功至关重要。应排除维生素 D 充足(例如,基线 25(OH)D>50 nmol/L)、肥胖(例如,体重指数>30 kg/m )和/或高维生素 D 反应指数的参与者。其次,应使用适当形式或剂量的维生素 D 进行干预。建议补充适当剂量的维生素 D,使 25(OH)D 水平保持在 75-100 nmol/L 之间。第三,需要注意对照组的“污染”。为了减少这种情况,理想情况下应包括受阳光照射干扰较小(例如居住在高纬度地区)或依从性更高(受补充含维生素 D 营养素干扰较小)的参与者。第四,结局测量应敏感以避免 II 类错误。对于骨密度、放射影像学骨关节炎和心血管疾病等结局,可能需要 3-5 年的随访期来观察变化。最后,精准临床试验可能是证明维生素 D 补充益处的唯一途径。